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ABSTRACT
Background The mortality impact of COVID-19 has thus
far been described in terms of crude death counts. We
aimed to calibrate the scale of the modelled mortality
impact of COVID-19 using age-standardised mortality
rates and life expectancy contribution against other,
socially determined, causes of death in order to inform
governments and the public.
Methods We compared mortality attributable to
suicide, drug poisoning and socioeconomic inequality
with estimates of mortality from an infectious disease
model of COVID-19. We calculated age-standardised
mortality rates and life expectancy contributions for the
UK and its constituent nations.
Results Mortality from a fully unmitigated COVID-19
pandemic is estimated to be responsible for
a negative life expectancy contribution of −5.96 years
for the UK. This is reduced to −0.33 years in the fully
mitigated scenario. The equivalent annual life
expectancy contributions of suicide, drug poisoning
and socioeconomic inequality-related deaths are
−0.25, −0.20 and −3.51 years, respectively. The
negative impact of fully unmitigated COVID-19 on life
expectancy is therefore equivalent to 24 years of
suicide deaths, 30 years of drug poisoning deaths and
1.7 years of inequality-related deaths for the UK.
Conclusion Fully mitigating COVID-19 is estimated to
prevent a loss of 5.63 years of life expectancy for the UK.
Over 10 years, there is a greater negative life expectancy
contribution from inequality than around six unmitigated
COVID-19 pandemics. To achieve long-term population
health improvements it is therefore important to take this
opportunity to introduce post-pandemic economic policies to
‘build back better’.
BACKGROUND
The COVID-19 pandemic has been tracked by daily
counting of cumulative numbers of confirmed cases
and deaths.1 The exponential growth in these num-
bers across countries has understandably created
anxiety and action from public health agencies and
governments internationally. Despite initial surveil-
lance and reporting of COVID-19 following stan-
dard infectious disease epidemiologic methods, the
subsequent reporting of COVID-19 mortality has
largely focused on crude death counts, arguably
not meeting the ‘rigorous standardisation and qual-
ity control of investigative methods [that] are essen-
tial in epidemiology’.2 A number of particular
limitations in the data have prevented a sufficient
understanding of the true impact of the pandemic
on mortality.
First, the counting of cases of COVID-19 within
and between countries has been dependent on the
case definition and the changes in that over time. At
the beginning of the outbreak in Wuhan, China,
cases were defined clinically before virological test-
ing was available. Then, as testing became partially
available, cases were defined as people with a travel
history from China, or contact with a known case,
and a positive virology test. Then, cases were
defined as people with a positive virology test irre-
spective of symptoms or history, although the avail-
ability of tests remained restricted.3 This is
problematic for epidemiological surveillance,
because limited availability of testing, and the self-
limiting nature of the infection for many, meant that
the case count underestimated the true incidence
within the population. For COVID-19 deaths, the
count was initially based on people who died within
hospital who had a positive virological test. This is
subsequently being extended in most countries to
include coding of deaths based on clinical opinion in
all settings. This raises a further issue because many
deaths will occur in people who die with, rather than
die of, COVID-19.
Deaths occur every day, and simply reporting the
cumulative number of deaths for any particular
cause, be that COVID-19 or anything else, will
always reveal a rising trend. Other causes of death
are not reported in this way. It is therefore difficult
for the public and policymakers to understand how
to interpret and compare these to other causes of
death.
The COVID-19 deaths reported are crude
death counts. They therefore do not take into
account the size of the population at risk (as
a crude rate does), nor the age and sex structure
of the population, in particular, how old the
population is (as an age-sex-standardised rate
does). In contrast, other causes of death such as
cancers and heart disease, and deaths attributable
to deprivation, poverty and other political and
socioeconomic causes such as austerity are
usually measured as differences in such standar-
dised rates, in Years of Life Lost (YLL), or life
expectancy contributions.4 Finally, the reported
crude death counts also do not account for com-
peting causes and how likely people dying from
COVID-19 were to have died relatively soon
from other causes.5 It is therefore difficult to
assess the scale of the mortality risk of COVID-19
relative to the background mortality risk in the
population.






















These problems of interpretation are very important. If
COVID-19 generates a substantially higher mortality rate across
all or part of the population than would otherwise have been
expected, this would support much more radical action to con-
trol the pandemic. On the other hand, if COVID-19 has little
additional impact on the mortality rate compared to what would
otherwise have been expected, then it may be that the negative
health impacts of the control measures (eg, due to the impacts of
closing down large sectors of the economy6) outweigh the posi-
tive impact of mitigating the pandemic.
Given the importance of all the above, the aim of this paper is
to apply rigorous epidemiological methods using consistent defi-
nitions to compare age-sex-standardisedmortality and life expec-
tancy contributions of mortality from COVID-19 with the total
attributable life expectancy impact of socioeconomic inequality,
and with two examples of causes of death which are experienced
particularly unequally and which have been the focus of some
recent policy attention: suicide and drug-related poisonings.
METHODS
Estimating COVID-19 mortality
The UK Government has based decisions on pandemic control
measures on the modelling of the Imperial College team on the
likely scale and timing of the pandemic. The estimate (published
on 16 March 2020) of the number of deaths in an unmitigated
epidemic in Great Britain (GB) is between 410 000 and 550 000
(with a best estimate of 510 000), and between 5600 and 48 000
in a fully mitigated epidemic (with a best estimate of 20 000).7
Estimated deaths by age group are not provided, but ‘infection
fatality ratios’ (the percentage of people who are infectedwho are
then expected to die) for 10-year age bands up to age 79 years,
with an open upper age band, are provided. Using the 2018
midyear population data from the Office for National Statistics
(ONS) for these age bands for GB and assuming that the propor-
tion of the population in each age group that become infected is
uniform, we weighted the deaths in each age group to achieve the
total number of deaths estimated by Ferguson et al. We fitted
a linear regression model to the logarithm of the infection fatality
rates in order to estimate the rate for each 5-year, rather than 10-
year, age bands up to age 90 years (online supplemental figure
S1). These rates were then applied to population data and the
total scaled to the estimated deaths in GB under the two scenarios
(mitigated and unmitigated). As a sensitivity analysis, we applied
the age distribution of the deaths certified with COVID-19 as the
underlying cause in England and Wales between March and
June 20208 to calculate the life expectancy impact.
Estimating suicide, drug poisoning and inequality-related
mortality
We obtained population counts for England, Northern Ireland,
Scotland and Wales for each year between 2013 and 2017, by
5-year age band and sex, from the Office for National Statistics
(ONS), National Records of Scotland (NRS) and the Northern
Ireland Statistics and Research Agency (NISRA). We also
obtained the count of all deaths by each nation’s deprivation
decile by age and sex, and for two specific causes of death
(suicide, including events of undetermined intent; and drug poi-
soning) by age and sex for each year between 2013 and 2017. The
ICD10 codes for suicide were X60-X84, Y10-Y34, Y87.0 and
Y87.2; and for drug-related poisonings were F11-F16, F18, F19,
X40-X44, X60-X64, X85 and Y10-Y14. The drug poisoning
deaths are coded using the broader definition, and the suicide
coding uses the older (pre-2011) codes. The definitions of suicide
and drug poisoning deaths overlap and cannot therefore be
summed.9 Following Lewer,10 we defined deaths due to inequal-
ity as all deaths higher than the rate of mortality in the least
deprived tenth of the population in each population. This is
akin to calculating the population attributable fraction of
inequality. Deprivation was measured using IMD2015 for
England, WIMD2014 for Wales, SIMD2016 for Scotland and
the 2010 Northern Ireland Multiple Deprivation Measure
(NIMDM) for Northern Ireland. We also performed
a sensitivity analysis which attributed all deaths above the age-
specific rate across every population compared to the least
deprived tenth of England (as the nation with the lowest mortal-
ity rate in the least deprived tenth).
Estimating the contribution of different causes to crude and
standardised mortality rates, and life expectancy
For crude deaths, we simply summed the reported number of
deaths in each age band (taking the 5-year mean between 2013
and 2017 for suicide, drug-related and inequality-related deaths).
For age-standardised deaths, we applied the age-specific deaths to
the 2013 European Standard Population to calculate directly
standardised estimates. Overall life expectancy was estimated
using the method detailed by Auger et al11 based on counts of
death and populations in 5-year age groups (together with deaths
as age 0, 1–4 and aged 90 and over). For COVD-19 and inequal-
ity deaths in Northern Ireland, we had to estimate the distribu-
tion between the 0–1 and 1–4 year age bands as this breakdown
was not available. The effect of COVID was estimated by adding
the predicted deaths under the two scenarios, recalculating the
life expectancy and taking the difference. The effect of the other
causes on life expectancy was estimated by subtracting the deaths
attributable to those causes, recalculating life expectancy and
taking the difference.
RESULTS
Table 1 provides the estimates of the unmitigated and fully miti-
gated mortality impact of the COVID-19 pandemic by age group
for the UK and its nations, based on the Imperial College model-
ling. It estimates that the majority of deaths will be in the older
age groups because the smaller population size is outweighed by
the higher mortality rates for these ages. For the UK overall there
are estimated to be 195 420 and 7664 deaths among those aged
80+ years in the unmitigated and mitigated scenarios, respec-
tively, with 28% of all deaths occurring under the age of 70 years
and 38% of all deaths occurring for those aged 80+ years. The
proportions are very similar across the nations.
Table 2 shows the annual (5-year mean) age-specific mortality
counts for suicide, drug poisoning and inequality-related mortal-
ity by nation. These causes have a much younger age distribution
of deaths compared to COVID-19, with the highest UK age-
specific mortality counts being among 45–49 year olds for sui-
cides and 40–44 year olds for drug poisonings. The peak age for
crude mortality due to inequality was 80–84 years but there was
a broad age distribution. Suicide and drug poisonings have lower
overall counts compared to mitigated COVID-19. However,
deaths due to inequality are seven times those of mitigated
COVID-19. The crude mortality is substantially higher for men
than women for suicide, drug poisonings and inequality (online
supplemental tables S1 and S2). The modelling of COVID-19
deaths was not available separately by sex. The sensitivity analysis
which used the least deprived tenth of the population of England
as the comparator increased the number of deaths attributable to
inequality slightly as the least deprived tenth of England has






















lower mortality than the equivalents across the other nations.
However, the impact on the overall results is small (online supple
mental table S3). Suicide, drug poisonings and inequalities all
generate mortality every year, and cumulatively over a few
years amount to greater total crude deaths than COVID-19. For
example, in 3.5 years the total death count for inequality-related
deaths overtakes the number of COVID-19 deaths in the UK in
the completely unmitigated scenario.
Table 3 compares the crude mortality, age-standardised
mortality and life expectancy contributions of the different
causes. The negative contribution to life expectancy for drug,
suicide and inequality-related deaths is much greater than the
contribution from the fully mitigated COVID-19 mortality.
The contribution to life expectancy of inequality-related
deaths is higher, and the contribution of COVID-19 deaths
lower, in Scotland and Northern Ireland compared to the UK
overall. The sensitivity analysis using the age distribution of
the underlying COVID-19 deaths in England and Wales
(online supplemental table S4) shows very similar results to
those based on the Imperial College modelling, stemming
from the predicted and actual age distributions being very
similar.
Table 1 Estimates of the potential mortality impact of COVID-19 on different age groups by applying assumptions to the imperial model
Age group (years) UK age distribution* Infection Fatality Ratio UK GB England & Wales Scotland Northern Ireland
Estimated number of deaths in each age group if there were a total of 510 000 deaths in GB
0 to 4 6% 0.002% 44 42 39 3 1
5 to 9 6% 0.003% 78 76 70 6 2
10 to 14 6% 0.006% 124 120 111 9 4
15 to 19 6% 0.010% 200 194 178 16 6
20 to 24 6% 0.017% 387 376 344 32 11
25 to 29 7% 0.028% 711 691 631 60 19
30 to 34 7% 0.048% 1189 1155 1059 96 34
35 to 39 7% 0.082% 1975 1920 1762 157 56
40 to 44 6% 0.139% 3061 2972 2728 243 89
45 to 49 7% 0.236% 5860 5694 5208 487 166
50 to 54 7% 0.400% 10 310 10 018 9125 893 292
55 to 59 6% 0.678% 16 066 15 611 14 165 1447 455
60 to 64 6% 1.150% 23 316 22 663 20 528 2135 652
65 to 69 5% 1.952% 36 574 35 613 32 378 3235 961
70 to 74 5% 3.311% 59 400 57 930 52 980 4950 1470
75 to 79 3% 5.617% 69 281 67 442 61 520 5922 1839
80 to 84 3% 9.528% 87 980 85 803 78 429 7374 2177
85 to 89 2% 16.164% 91 370 89 177 81 913 7264 2192
90+ 1% 35.716% 115 091 112 502 104 240 8262 2589
Total 523 016 510 000 467 409 42 591 13 016
Estimated number of deaths in each age group if there were a total of 20 000 deaths in GB
0 to 4 6% 0.002% 2 2 2 0 0
5 to 9 6% 0.003% 3 3 3 0 0
10 to 14 6% 0.006% 5 5 4 0 0
15 to 19 6% 0.010% 8 8 7 1 0
20 to 24 6% 0.017% 15 15 13 1 0
25 to 29 7% 0.028% 28 27 25 2 1
30 to 34 7% 0.048% 47 45 42 4 1
35 to 39 7% 0.082% 77 75 69 6 2
40 to 44 6% 0.139% 120 117 107 10 3
45 to 49 7% 0.236% 230 223 204 19 7
50 to 54 7% 0.400% 404 393 358 35 11
55 to 59 6% 0.678% 630 612 555 57 18
60 to 64 6% 1.150% 914 889 805 84 26
65 to 69 5% 1.952% 1434 1397 1270 127 38
70 to 74 5% 3.311% 2329 2272 2078 194 58
75 to 79 3% 5.617% 2717 2645 2413 232 72
80 to 84 3% 9.528% 3450 3365 3076 289 85
85 to 89 2% 16.164% 3583 3497 3212 285 86
90+ 1% 35.716% 4513 4412 4088 324 102
Total 20 510 20 000 18 330 1670 510
*ONS 2018 mid-population estimate. The population profiles for each nation/GB/UK were used to weight the estimates, but these are not shown because they are very similar to the estimates for
the UK overall. GB, Great Britain; UK, United Kingdom.






















The lower age distribution of suicide, drug poisoning and
inequality-related deaths reduces further the difference between
them and unmitigated COVID-19 when using the age-
standardised and life expectancy contribution measures, such
that the negative contribution to life expectancy of unmitigated
COVID-19 represents the equivalent of the inequality-related
deaths occurring over only 1.7 years for the UK overall. This
means that over 10 years there is a greater negative life expec-
tancy contribution from inequality than about six completely
unmitigated COVID-19 pandemics for the UK overall. The esti-
mated life expectancy impacts of different numbers of crude
COVID-19 deaths are provided in online supplemental figure
S2 and table S5.
DISCUSSION
Main results
COVID-19 represents a large and urgent mortality risk for popu-
lations across the world. However, counting cumulative crude
deaths is an unhelpful means of ascertaining the scale of this risk.
Comparing standardised mortality rates and life expectancy con-
tributions of COVID-19 and three causes of death that are
strongly socially determined—suicide, drug poisoning and
inequality-related deaths—reveals that the mortality from
a fully unmitigated COVID-19 pandemic is modelled to be
responsible for the negative life expectancy contribution that
occurs due to the cumulative inequality-related deaths over the
course of around 1.7 years. Putting this another way, over a 10-
year period if there were around six unmitigated pandemics on
the scale of the current COVID-19 pandemic, the impact on life
expectancy would be less than that of inequalities.
Table 2 Estimated number of deaths due to suicide, drug poisonings and inequality-related deaths by age (2013–2017 annualised mean, total
population)
Drug poisonings Suicide Inequality
Age group (years) UK GB E&W Sco NI UK GB E&W Sco NI UK GB E&W Sco NI
0–4 1 1 1 0 0 4 4 3 1 0 1040 1043 983 60 −3
5–9 1 1 1 0 0 1 1 1 0 0 97 93 92 1 4
10–14 3 3 2 1 0 20 18 15 3 2 58 54 45 9 4
15–19 63 59 46 13 4 195 182 161 20 14 280 255 222 33 25
20–24 194 181 150 31 13 395 364 321 43 31 266 221 152 69 46
25–29 356 339 271 67 17 461 428 370 58 33 583 562 440 122 21
30–34 528 508 395 114 19 519 483 422 61 36 1160 1122 890 232 38
35–39 672 655 516 139 17 531 500 432 68 31 1958 1880 1557 324 78
40–44 734 719 558 161 15 663 633 547 86 31 3189 3119 2651 467 70
45–49 632 618 490 127 14 737 703 611 92 34 5032 4853 4226 627 179
50–54 467 456 365 91 11 684 653 574 80 31 6470 6287 5412 876 183
55–59 284 277 232 46 6 523 504 442 62 19 8377 8149 6993 1156 228
60–64 189 184 158 26 5 365 350 309 41 15 11 473 11 197 9707 1490 276
65–69 116 115 100 15 2 287 278 249 29 9 16 053 15 629 13 609 2019 424
70–74 74 72 63 9 2 209 204 180 23 6 18 497 18 070 15 649 2421 426
75–79 56 55 49 6 1 162 158 142 16 4 21 398 20 961 18 371 2591 436
80–84 41 40 39 2 1 128 127 118 9 1 22 305 21 982 19 501 2481 322
85–89 29 29 27 2 0 95 94 88 5 1 17 154 16 886 15 194 1692 268
90+ 22 22 21 1 0 56 56 52 4 0 11 957 11 799 11 319 481 158
Total 4460 4334 3483 850 126 6038 5739 5039 701 298 147 346 144 164 127 013 17 150 3182
E&W, England & Wales; GB, Great Britain; NI, Northern Ireland; Sco, Scotland; UK, United Kingdom.











523 016 510 000 467 409 42 591 13 016
COVID-19 fully
mitigated
20 510 20 000 18 330 1670 510
Drug poisonings 4460 4334 3483 850 126
Suicide 6038 5739 5039 701 298
Inequality-related 147 346 144 164 127 013 17 150 3182
Age-standardised mortality per 100 000
COVID-19
unmitigated
903 903 903 899 910
COVID-19 fully
mitigated
35 35 35 35 36
Drug poisonings 7 7 6 16 7
Suicide 9 9 9 13 16
Inequality-related 253 254 245 346 210
Impact on life expectancy (years)
COVID-19
unmitigated
−5.96 −5.96 −6.03 −5.26 −5.76
COVID-19 fully
mitigated
−0.33 −0.33 −0.34 −0.29 −0.32
Drug poisonings −0.20 −0.20 −0.17 −0.45 −0.22
Suicide −0.25 −0.25 −0.24 −0.34 −0.49
Inequality-related −3.51 −3.53 −3.40 −4.73 −3.02
GB, Great Britain; UK, United Kingdom.























There is an urgency in being able to calibrate the mortality risk
due to COVID-19 in order to be able to ascertain the appropriate
level of control measures required. This study therefore uses the
available modelled data that have been used to justify the control
measures in place at the time of writing alongside routinely
available and published data on other mortality risks that have
been present in the UK and around the world for some time.12
There are, however, a number of limitations. The Imperial model
upon which our study is based, does not describe an endemic
infection scenario which could transpire. We have had to model
the age-specific mortality of COVID-19 by 5-year age band as
this was not available in the Imperial College data. The exponen-
tial relationship between age and COVID-19 mortality alongside
the open upper age bound in our data make the estimates at this
upper age more uncertain. Similarly, the Imperial College mod-
elling does not provide estimates by sex, although the emerging
evidence suggests that the mortality rates are higher among men.
This means that the life expectancy impacts of COVID-19 pro-
vided in this paper are likely to be overestimated because men
have a systematically lower life expectancy than women and so
the loss of lifespan for men will be less. It is also recognised that
COVID-19 mortality rates are higher among those with co-
morbidities for any given age-sex group.13 Our modelling does
not differentiate between groups on this basis and is therefore
likely to be a further source of systematic bias which overesti-
mates the mortality impact of COVID-19. For these reasons, the
impacts onmortality of COVID-19 estimated here are likely to be
substantially higher than reality. Our estimate of the attributable
fraction of socioeconomic inequality on life expectancy does not
attempt to consider the impact of specific policies to reduce
inequalities, but instead estimates the total life expectancy loss
attributable to socioeconomic inequality.
How this fits with the existing literature
Other estimates of the impact on life expectancy of COVID-19
pandemic have been made which include all excess deaths (ie,
including those directly due to COVID-19 and as a result of the
unintended consequences of the control measures). These are, as
expected, higher than our estimates of the direct impact provided
here.14 The COVID-19 pandemic and health inequality both
clearly require a radical policy response to reduce the associated
mortality. Health inequalities have long been recognised as an
important policy issue12 15 but there has been little or no progress
in reducing them over at least 40 years.16 For COVID-19, it is
also important to ensure that the physical distancing measures
(the substantive difference between an unmitigated and fully
mitigated COVID-19 pandemic) do not cause more population
health damage than the gain achieved through mitigation.17
Physical distancing is likely to have marked impacts on the econ-
omy, incomes, employment, social isolation, physical activity and
education. A rapid Health Impact Assessment has identified that
the potential for unintended negative health consequences is very
large.18 Although many of the relevant mechanisms and negative
impacts have been reduced to some extent in the UK and else-
where (eg, through the policy of funding part of the wages of staff
who have been furloughed), it is highly unlikely that these can be
reduced to zero, particularly given the scale of the economic
shock.19
Implications
The policy response to public health challenges should match the
mortality risk. The analysis in this paper indicates that the long-
term life expectancy impact of inequalities is substantially greater
than even an unmitigated COVID-19 pandemic because the pro-
blem of inequalities is ongoing. The rapid policy response to
COVID-19 demonstrates what governments can and should do
in the face of a massive population health challenge. Yet the
mortality risk from the socially generated causes compared
here, as well as many others, over only a few short years con-
tributes many more deaths on all metrics than COVID-19. It is
interesting to compare the radical government action in the face
of the COVID-19 threat but the lack of effective policy interven-
tions to reduce income, wealth and power inequalities (eg,
through social security benefit values, progressive taxes, owner-
ship of capital and so on15 20 21) to reduce inequality-related
mortality. The post-COVID-19 pandemic period should be used
to ‘build back better’ and ensure that society and the economy in
the future provides the basis to reduce social inequalities in health
and all avoidable causes of death.6 Future monitoring and report-
ing of COVID-19 mortality should include age-standardised
mortality rates and life expectancy contributions for set time
periods rather than simply reporting cumulative crude deaths.
The estimation of the life expectancy contribution of COVID-19
should also be repeated later in the pandemic when actual (rather
than modelled) mortality data are available for the population
overall and stratified by sex.
CONCLUSION
The mortality risk from COVID-19 is substantial and if unmiti-
gated could lead to a decline of 5.96 years of life expectancy. The
risks from recurrent deaths, such as those due to inequality, will
quickly surpass those due to COVID-19. Building the economy
back better such that inequality-related deaths are reduced in the
future is as important as physical distancing is now for future
population health.
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